DiaMedica Therapeutics Inc. (DMAC) Stock

DiaMedica Therapeutics Inc. (DMAC) is a Healthcare stock trading at $5.82 (as of 2026-06-18), with a market capitalization of $322.76M and a trailing P/E of -8.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. Its pipeline includes DM199, a recombinant human tissue kallikrein-1 protein in Phase 2 trials for chronic kidney disease associated with diabetes and Phase 2/3 trials for acute ischemic stroke, and DM300 in pre-clinical development for inflammatory diseases.

Valuation — source: SEC EDGAR (first-party)
Price	$5.82
Market Cap	$322.76M
P/E Ratio	-8.7
EV / EBITDA	-8.2
Price / Book	6.45
Price / Sales	179.61
DCF Value (model)	$-8.90
DCF Upside vs Price	-252.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.67M
Net Margin	-1963.2%
Return on Equity	-74.3%
Current Ratio	9.11
Revenue Growth (YoY)	-27.5%
EPS Growth (YoY)	16.7%
FCF Growth (YoY)	31.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	31.09 (safe)

Valuation vs Sector & Industry
Stock P/E	-8.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-141.5%
vs Industry	-151.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	COOPERMAN LEON G ($13.68M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dietrich John Pauls
Employees	27
Country	US
IPO Date	2012-08-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.